Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 643

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 643
---
2024, Tvardi issued and sold or will issue and sell an aggregate of $28,297,679. The following table summarizes the Convertible Notes purchased by holders of more than 5% of Tvardi’s capital stock and entities affiliated with its executive officers and members of its board of directors.

| ​                                      | ​ |                  ​ |
| ​                                      | ​ |          Aggregate |
| ​                                      | ​ |   Principal Amount |
| ​                                      | ​ | of the Convertible |
| ​                                      | ​ |              Notes |
| Participants(1)                        | ​ |                 -$ |
| Entities affiliates with Slate Path(2) | ​ |          2,000,000 |
| BioMatrix Partners Ltd.(6)             |   |          1,000,000 |

| (1) | Additional details regarding these stockholders and their equity holdings are included in this proxy statement/prospectus under the section titled “Principal Stockholders of Tvardi.” |

| (2) | Consists of (i) $1,768,000 in Convertible Notes purchased by Slate Path Master Fund LP and (ii) $232,000 in Convertible Notes purchased by SPB Master Fund LP (together with Slate Path Master Fund LP and other affiliates, Slate Path). Jamie McNab is a member of Tvardi’s board of directors and a Partner of Slate Path Capital LP, which is the investment manager of Slate Path Master Fund LP and SPB Master Fund LP. Mr. McNab may be deemed to share the power to direct the disposition and vote of any shares received by Slate Path in the conversion of such Convertible Notes, but disclaims beneficial ownership of all shares held by Slate Path except to any pecuniary interest therein. |

356

| (3) | Wallace Hall is a member of Tvardi’s board of directors and a general partner of BioMatrix Partners Ltd. Mr. Hall may be deemed to share the power to direct the disposition and vote of any shares received by BioMatrix Partners Ltd. in the conversion of such Convertible Notes, but disclaims beneficial ownership of all shares held by BioMatrix Partners Ltd. except to any pecuniary interests therein. |

Series B Preferred Stock Financing In multiple closings held between June 3, 2021 and June 17, 2021, Tvardi issued and sold an aggregate of 20,055,539 shares of its Series B redeemable convertible preferred stock, $0.001 par value per share,